Phase II Trial of pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
Latest Information Update: 26 Feb 2025
At a glance
- Drugs MVI 118 (Primary) ; MVI 816 (Primary) ; Pembrolizumab (Primary) ; Sargramostim (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
Most Recent Events
- 29 May 2024 Status changed from recruiting to active, no longer recruiting.
- 17 Apr 2024 Planned End Date changed from 1 Dec 2025 to 1 Oct 2026.
- 17 Apr 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Jan 2025.